Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: A cross-sectional study

BMC Endocrine Disorders

Volumn 14, Issue , 2014, Pages

  Hong, Nam S ^a   Kim, Jeong Gook ^b   Lee, Yu Mi ^a   Kim, Hyun Woo ^c   Kam, Sin ^a   Kim, Keon Yeop ^a   Kim, Ki Su ^a   Lee, Duk Hee ^a,d  

^a Kyungpook National University School of Medicine   (South Korea)

^b Gachon University   (South Korea)

^c Daegu Medical Center   (South Korea)

^d Kyungpook National University   (South Korea)

Author keywords

Impaired fasting glucose; Obesity; Type 2 diabetes; Glutamyltransferase (GGT)

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK; SEX DIFFERENCE; ANALYSIS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; MIDDLE AGED; NUTRITION; PATHOPHYSIOLOGY; PROGNOSIS; REFERENCE VALUE; RISK FACTOR;

BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; OBESITY; PROGNOSIS; REFERENCE VALUES; RISK FACTORS;

EID: 84904080081     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-14-57     Document Type: Article

References (31)

1. Andre P, Balkau B, Born C, Charles MA, Eschwege E. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006, 49:2599-2603.
2. Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y. Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring) 2012, 20:842-848.
3. Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomileto J. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004, 89:5410-5414.
4. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998, 21:732-737.
5. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, Blomhoff R, Jacobs DR. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia 2003, 46:359-364.
6. Shin JY, Hwang JH, Jeong JY, Kim SH, Moon JD, Roh SC, Kim YW, Kim Y, Leem JH, Ju YS, Hong YS, Ha EH, Lee YH, Kim DH, Lee DH. The association of central obesity with type 2 diabetes among Koreans according to the serum gamma-glutamyltransferase level: Korean genome and epidemiology study. J Prev Med Public Health 2009, 42:386-391.
7. Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem 2007, 53:1092-1098.
8. Fujita M, Ueno K, Hata A. Association of gamma-glutamyltransferase with incidence of type 2 diabetes in Japan. Exp Biol Med (Maywood) 2010, 235:335-341.
9. Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005, 258:527-535.
10. Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003, 49:1358-1366.
11. Association Diabetes Association Standards of medical care in diabetes--2013. Diabetes Care 2013, 36(Suppl 1):S11-S66. Association Diabetes Association.
12. Nakanishi N, Nakamura K, Suzuki K, Tatara K. Lifestyle and the development of increased serum gamma-glutamyltransferase in middle-aged Japanese men. Scand J Clin Lab Invest 2000, 60:429-438.
13. Ministry for Health and welfare affairs Kcfdcap Guideline for use of KNHANES 2012, Ministry for Health and welfare affairs Kcfdcap.
14. Persijn JP, van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem 1976, 14:421-427.
15. Kawamoto R, Tabara Y, Kohara K, Miki T, Ohtsuka N, Kusunoki T, Takayama S, Abe M. Serum gamma-glutamyl transferase within its normal concentration range is related to the presence of impaired fasting glucose and diabetes among Japanese community-dwelling persons. Endocr Res 2011, 36:64-73.
16. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003, 254:287-295.
17. Shin JY, Lim JH, Koh DH, Kwon KS, Kim YK, Kim HC, Lee YC, Lee JH, Nam MS, Hong SB, Park SG. [Serum gamma-glutamyltransferase levels and the risks of impaired fasting glucose in healthy men: a 2-year follow-up]. J Prev Med Public Health 2006, 39:353-358.
18. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
19. Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res 2004, 38:535-539.
20. Lee DH, Jacobs DR. Is serum gamma-glutamyltransferase a marker of exposure to various environmental pollutants?. Free Radic Res 2009, 43:533-537.
21. Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?. Am J Gastroenterol 2003, 98:955-956.
22. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24:816-823.
23. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
24. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006, 52:601-623.
25. Airaksinen R, Rantakokko P, Eriksson JG, Blomstedt P, Kajantie E, Kiviranta H. Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care 2011, 34:1972-1979.
26. Gasull M, Pumarega J, Tellez-Plaza M, Castell C, Tresserras R, Lee DH, Porta M. Blood concentrations of persistent organic pollutants and prediabetes and diabetes in the general population of Catalonia. Environ Sci Technol 2012, 46:7799-7810.
27. Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, Jacobs DR. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care 2006, 29:1638-1644.
28. Sims EA. Are there persons who are obese, but metabolically healthy?. Metabolism 2001, 50:1499-1504.
29. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, Engelgau MM, Vinicor F. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004, 27:2806-2812.
30. McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007, 167:642-648.
31. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004, 39:754-763.